Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
25.54
Nov 17 • 3:15 PM ET Dollar change-0.23 Percentage change(-0.87%)
Aftermarket Close
25.54
Aftermarket • 4:15 PM ET Dollar change0.00 Percentage change(0.00%)
Category
Global or ExUS Equities - Industry Sector
Sponsor
Amplify Investments
Fund Family
Index
VettaFi Weight Loss Drug & Treatment Ind...
Index Weighting
Active/Passive
Expense
0.59%
Inverse/Leveraged
IPO
May 21, 2024
Asset Type
Equities (Stocks)
ETF Type
Bond Type
Average Maturity
Commodity Type
Quant Type
ESG Type
Dividend Type
Structure Type
Growth/Value
Market Cap
Option/Short
No / Yes
Tags
Tags
Tags
Tags
Tags
-
Tags
-
Tags
-
Sector/Theme
Region
SMA20
-0.22%
SMA50
1.01%
SMA200
0.93%
Return% 1Y
5.20%
Return% 3Y
-
Return% 5Y
-
Return% 10Y
Return% SI
Flows% 1M
-13.06%
Flows% 3M
-0.34%
Flows% YTD
80.54%
Flows% 1Y
Flows% 3Y
Flows% 5Y
Trades
Total Holdings
22
AUM
5.16M
NAV/sh
52W High
27.94 -8.60%
52W Low
23.40 9.14%
Volatility
0.96% 0.69%
ATR (14)
0.37
RSI (14)
49.29
Beta
0.40
Rel Volume
0.91
Avg Volume
1.15K
Volume
1,050
Perf Week
-2.77%
Perf Month
4.66%
Perf Quarter
-7.24%
Perf Half Y
5.89%
Perf YTD
1.26%
Perf Year
2.22%
Perf 3Y
-
Perf 5Y
-
Perf 10Y
-
Prev Close
25.76
Price
25.54
Change %
-0.87%
Amplify Weight Loss Drug & Treatment ETF seeks investment results that generally correspond to the performance (before fees and expenses) of the VettaFi Weight Loss Drug & Treatment Index. The fund's manager invests at least 80% of its net assets (plus borrowings for investment purposes) in securities that comprise the index. The index is comprised of global companies who are manufacturers in the GLP-1 agonist pharmaceutical business or who enable such business. GLP-1 agonists (glucagon-like peptide) seek to lower blood sugar levels and reduce appetite and promote fullness, with the ultimate potential for weight loss. The fund is non-diversified.